18F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study. (July 2021)
- Record Type:
- Journal Article
- Title:
- 18F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study. (July 2021)
- Main Title:
- 18F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study
- Authors:
- Zhang, Min
Ni, You
Zhou, Qinming
He, Lu
Meng, Huanyu
Gao, Yining
Huang, Xinyun
Meng, Hongping
Li, Peihan
Chen, Meidi
Wang, Danni
Hu, Jingyi
Huang, Qiu
Li, Yao
Chauveau, Fabien
Li, Biao
Chen, Sheng - Abstract:
- Abstract: Background: Amyloid positron emission tomography (PET) can measure in-vivo demyelination in patients with multiple sclerosis (MS). However, the value of 18 F-labeled amyloid PET tracer, 18 F-florbetapir in the longitudinal study for monitoring myelin loss and recovery has not been confirmed. Methods: From March 2019 to September 2020, twenty-three patients with MS and nine healthy controls (HCs) underwent a hybrid PET/MRI at baseline and expanded disability status scale (EDSS) assessment, and eight of 23 patients further underwent follow-up PET/MRI. The distribution volume ratio (DVR) and standard uptake value ratio (SUVR) of 18 F-florbetapir in damaged white matter (DWM) and normal-appearance white matter (NAWM) were obtained from dynamic and static PET acquisition. Diffusion tensor imaging-derived parameters were also calculated. Data were expressed as mean ± standard deviation with 99% confidence interval (99%CI). Finding: The mean DVR (1.08 ± 0.12, 99%CI [1.02 ~ 1.14]) but not the mean SUVR of DWM lesions was lower than that of NAWM in patients with MS (1.25 ± 0.10, 99%CI [1.20 ~ 1.31]) and HCs (1.29 ± 0.08, 99%CI [1.23 ~ 1.36]). A trend toward lower mean fractional anisotropy (374.95 ± 45.30 vs. 419.07 ± 4.83) and higher mean radial diffusivity (0.45 ± 0.05 vs. 0.40 ± 0.01) of NAWM in patients with MS than those in HCs was found. DVR decreased in DWM lesions with higher MD (rho = -0.261, 99%CI [-0.362 ~ -0.144]), higher AD (rho = -0.200, 99%CI [-0.318 ~Abstract: Background: Amyloid positron emission tomography (PET) can measure in-vivo demyelination in patients with multiple sclerosis (MS). However, the value of 18 F-labeled amyloid PET tracer, 18 F-florbetapir in the longitudinal study for monitoring myelin loss and recovery has not been confirmed. Methods: From March 2019 to September 2020, twenty-three patients with MS and nine healthy controls (HCs) underwent a hybrid PET/MRI at baseline and expanded disability status scale (EDSS) assessment, and eight of 23 patients further underwent follow-up PET/MRI. The distribution volume ratio (DVR) and standard uptake value ratio (SUVR) of 18 F-florbetapir in damaged white matter (DWM) and normal-appearance white matter (NAWM) were obtained from dynamic and static PET acquisition. Diffusion tensor imaging-derived parameters were also calculated. Data were expressed as mean ± standard deviation with 99% confidence interval (99%CI). Finding: The mean DVR (1.08 ± 0.12, 99%CI [1.02 ~ 1.14]) but not the mean SUVR of DWM lesions was lower than that of NAWM in patients with MS (1.25 ± 0.10, 99%CI [1.20 ~ 1.31]) and HCs (1.29 ± 0.08, 99%CI [1.23 ~ 1.36]). A trend toward lower mean fractional anisotropy (374.95 ± 45.30 vs. 419.07 ± 4.83) and higher mean radial diffusivity (0.45 ± 0.05 vs. 0.40 ± 0.01) of NAWM in patients with MS than those in HCs was found. DVR decreased in DWM lesions with higher MD (rho = -0.261, 99%CI [-0.362 ~ -0.144]), higher AD (rho = -0.200, 99%CI [-0.318 ~ -0.070]) and higher RD (rho = -0.198, 99%CI [-0.313 ~ -0.075]). Patients' EDSS scores were reduced ( B = 0.04, 99%CI [-0.005 ~ 0.084]) with decreased index of global demyelination in the longitudinal study. Interpretation: Our exploratory study suggests that dynamic 18 F-florbetapir PET/MRI may be a very promising tool for quantitatively monitoring myelin loss and recovery in patients with MS. Funding: Shanghai Pujiang Program, Shanghai Municipal Key Clinical Specialty, Shanghai Shuguang Plan Project, Shanghai Health and Family Planning Commission Research Project, Clinical Research Plan of SHDC, French-Chinese program "Xu Guangqi". … (more)
- Is Part Of:
- EClinicalMedicine. Volume 37(2021)
- Journal:
- EClinicalMedicine
- Issue:
- Volume 37(2021)
- Issue Display:
- Volume 37, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 37
- Issue:
- 2021
- Issue Sort Value:
- 2021-0037-2021-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-07
- Subjects:
- 18F-florbetapir -- PET/MRI -- Demyelination -- Myelin loss and recovery -- Multiple sclerosis
Medicine -- Research -- Periodicals
Medical policy -- Periodicals
Clinical Medicine
Health Policy
Public Health
Medical policy
Medicine -- Research
Periodical
Electronic journals
Periodicals
613 - Journal URLs:
- https://www.sciencedirect.com/science/journal/25895370 ↗
http://www.sciencedirect.com/ ↗ - DOI:
- 10.1016/j.eclinm.2021.100982 ↗
- Languages:
- English
- ISSNs:
- 2589-5370
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17784.xml